Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Bouhnik Y; Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group; Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif. Amiot A, et al. Among authors: vaysse t. Clin Gastroenterol Hepatol. 2016 Nov;14(11):1593-1601.e2. doi: 10.1016/j.cgh.2016.02.016. Epub 2016 Feb 22. Clin Gastroenterol Hepatol. 2016. PMID: 26917043
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Gagniere C, Bouhnik Y; OBSERV-IBD study group and the GETAID. Amiot A, et al. Among authors: vaysse t. Aliment Pharmacol Ther. 2017 Aug;46(3):310-321. doi: 10.1111/apt.14167. Epub 2017 Jun 8. Aliment Pharmacol Ther. 2017. PMID: 28593685
Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.
Martineau C, Flourié B, Wils P, Vaysse T, Altwegg R, Buisson A, Amiot A, Pineton de Chambrun G, Abitbol V, Fumery M, Hébuterne X, Viennot S, Laharie D, Beaugerie L, Nancey S, Sokol H; Goli-Crohn Study Group. Martineau C, et al. Among authors: vaysse t. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1077-1084. doi: 10.1111/apt.14371. Epub 2017 Oct 13. Aliment Pharmacol Ther. 2017. PMID: 29027693
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A; GETAID OBSERV-IBD study group. Tadbiri S, et al. Among authors: vaysse t. Aliment Pharmacol Ther. 2018 Feb;47(4):485-493. doi: 10.1111/apt.14419. Epub 2017 Dec 18. Aliment Pharmacol Ther. 2018. PMID: 29250803
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y; OBSERV-IBD study group, the GETAID. Amiot A, et al. Among authors: vaysse t. Aliment Pharmacol Ther. 2019 Jul;50(1):40-53. doi: 10.1111/apt.15294. Epub 2019 Jun 5. Aliment Pharmacol Ther. 2019. PMID: 31165509
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.
Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV Jr, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F; GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*. Dulai PS, et al. Aliment Pharmacol Ther. 2020 Mar;51(5):553-564. doi: 10.1111/apt.15609. Epub 2019 Dec 22. Aliment Pharmacol Ther. 2020. PMID: 31867766 Free PMC article.
IgG4-Related Disease in Monozygotic Twins: A Case Report.
Grados A, Vaysse T, Ebbo M, Carbonnel F, Schleinitz N. Grados A, et al. Among authors: vaysse t. Ann Intern Med. 2017 Jan 17;166(2):153-155. doi: 10.7326/L16-0122. Ann Intern Med. 2017. PMID: 28114468 No abstract available.
Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-Biroulet L, Simon M, Viennot S, Bouhnik Y. Lair-Mehiri L, et al. Among authors: vaysse t. Dig Liver Dis. 2020 Mar;52(3):268-273. doi: 10.1016/j.dld.2019.10.003. Epub 2019 Nov 13. Dig Liver Dis. 2020. PMID: 31732444
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.
Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F. Chaput N, et al. Among authors: vaysse t. Ann Oncol. 2019 Dec 1;30(12):2012. doi: 10.1093/annonc/mdz224. Ann Oncol. 2019. PMID: 31408090 Free article. No abstract available.
16 results